Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
November 04, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight The rising prevalence of urticaria...
Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair) Dominate the Market
October 04, 2024 05:44 ET
|
Research and Markets
Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "Chronic Urticaria: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This report provides a data-driven overview of...
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:30 ET
|
InflaRx N.V.
Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...
InflaRx Hosts R&D Event Highlighting the Promise of INF904
June 05, 2024 12:00 ET
|
InflaRx N.V.
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...
Global Vitiligo Treatment Market 2023: Unpacking the Potential of Antihistamines, H2 Antagonists and Tricyclic Antidepressants
October 30, 2023 05:43 ET
|
Research and Markets
Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. The global vitiligo treatment market is expected...